# OnCo record jaspac-01 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/jaspac-01/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "jaspac-01" ;
  schema:name "JASPAC 01"@en ;
  schema:alternateName "JASPAC-01"@en, "JASPAC01"@en ;
  schema:description "JASPAC 01 found that six months of the oral fluoropyrimidine S-1 after pancreatic cancer surgery nearly doubled five-year survival compared with gemcitabine in Japanese patients, 44 against 24 percent, which made S-1 the adjuvant standard in Japan; the result has never been tested in Western patients, who metabolise the drug differently."@en ;
  schema:url <https://onco.cc/trials/jaspac-01/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(16)30583-9>, <https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000794>, <https://doi.org/10.1200/JCO.2012.43.3680> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/tegafur-gimeracil-oteracil/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/taiho/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/> .